Core Viewpoint - NVIDIA Corporation is a leading technology company known for its GPUs and AI processors, facing competition from AMD and Intel in the semiconductor industry [1] Group 1: Financial Performance - NVIDIA's fiscal Q4 performance has been strong, driven by robust demand in the data center sector, contributing to significant revenue growth [3] - The company has a market capitalization of approximately $4.51 trillion, with a current stock price of $185.18, reflecting a 5.34% decrease [5] Group 2: Market Outlook - RBC Capital has set a price target of $250 for NVDA, indicating a potential upside of 34.97% from its trading price of $185.23 [2][6] - Investor concerns have been raised regarding a potential bubble in the AI processor market, particularly following NVIDIA's latest sales forecast [4][6] Group 3: Industry Challenges - A global shortage of gaming chips is expected to persist until year-end, impacting the video game industry [3] - Despite impressive earnings, NVIDIA is optimizing its operations to address power constraints in AI compute scaling [4][6]

Core Viewpoint - Certara Inc. is a significant entity in the Medical - Biomedical and Genetics industry, focusing on software and services that expedite drug development. The company has received an "Outperform" rating from Leerink Partners, indicating a positive outlook for investors [1][5]. Financial Performance - The recent earnings report indicated a quarterly earnings per share (EPS) of $0.09, which was below the Zacks Consensus Estimate of $0.11, resulting in a negative surprise of 20.57%. This EPS also represents a decline from $0.15 in the same quarter last year [2][5]. - Certara reported quarterly revenue of $103.65 million for the period ending December 2025, slightly exceeding the Zacks Consensus Estimate by 0.41%. This revenue reflects an increase from $100.36 million reported in the same quarter of the previous year [3][5]. Stock Performance - Certara's stock is currently trading at $6.61, showing a minor increase of 0.23% or $0.015. The stock has fluctuated between a low of $6.04 and a high of $6.66 on the same day. Over the past year, the stock reached a high of $15.38 and a low of $6.04 [4]. - The company has a market capitalization of approximately $1.05 billion, with a trading volume of 2,780,555 shares [4].

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

Core Insights - Alignment Healthcare reported a revenue of $1.01 billion for the quarter ended December 2025, marking a 44.4% increase year-over-year and exceeding the Zacks Consensus Estimate by 1.1% [1] - The company's EPS was -$0.05, an improvement from -$0.16 in the same quarter last year, resulting in a surprise of 67.04% compared to the consensus estimate of -$0.15 [1] Financial Performance Metrics - Medical Benefit Ratio was reported at 87.7%, which is better than the estimated 89.1% by analysts [4] - Health Plan Membership at the end of the quarter was 236,300, slightly above the estimated 233,752 [4] - Revenues from earned premiums reached $1 billion, surpassing the estimate of $990.31 million, reflecting a 45.1% increase year-over-year [4] - Other revenues were reported at $9.01 million, below the estimated $10.57 million, indicating a 4.7% decline compared to the previous year [4] Stock Performance - Over the past month, shares of Alignment Healthcare have decreased by 8.8%, contrasting with a 0.6% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Performance - Progyny reported revenue of $318.4 million for the quarter ended December 2025, reflecting a 6.7% increase year-over-year [1] - Earnings per share (EPS) for the quarter was $0.48, up from $0.42 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $303.93 million by 4.76% [1] - The company delivered an EPS surprise of 25.49%, with the consensus EPS estimate being $0.38 [1] Key Metrics - Utilization for female-only services was 0.5%, matching the two-analyst average estimate [4] - Average members reached 6,707, surpassing the two-analyst average estimate of 6,586 [4] - Revenue from pharmacy benefit services was $109.8 million, slightly below the estimated $110.78 million, representing a year-over-year decrease of 1.1% [4] - Revenue from fertility benefit services was $208.6 million, exceeding the three-analyst average estimate of $192.06 million, with a year-over-year increase of 11.3% [4] Stock Performance - Progyny's shares have returned -13.1% over the past month, while the Zacks S&P 500 composite has increased by 0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - CubeSmart (CUBE) reported a revenue of $282.69 million for the quarter ended December 2025, marking a year-over-year increase of 22.2% and a surprise of +0.79% over the Zacks Consensus Estimate of $280.47 million [1] - The earnings per share (EPS) for the same period was $0.64, compared to $0.45 a year ago, although it fell short of the consensus EPS estimate of $0.66, resulting in an EPS surprise of -2.75% [1] Financial Performance Metrics - Property management fee income was reported at $9.64 million, which is below the three-analyst average estimate of $10.16 million, reflecting a year-over-year decline of -7.3% [4] - Rental income reached $240.93 million, slightly below the $243.88 million average estimate based on two analysts, but showed a year-over-year increase of +5.6% [4] - Other property-related income was reported at $32.13 million, exceeding the two-analyst average estimate of $30.87 million, with a year-over-year change of +10.4% [4] - Net Earnings Per Share (Diluted) was $0.35, compared to the two-analyst average estimate of $0.37 [4] Stock Performance - CubeSmart's shares have returned +7.1% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Sweetgreen, Inc. reported a revenue of $155.19 million for the quarter ended December 2025, reflecting a year-over-year decline of 3.6% [1] - The earnings per share (EPS) for the same period was -$0.42, compared to -$0.25 a year ago, indicating a worsening financial performance [1] - The reported revenue was 2.82% lower than the Zacks Consensus Estimate of $159.69 million, and the EPS was 36.36% below the consensus estimate of -$0.31 [1] Financial Performance Metrics - Same-store sales decreased by 11.5%, slightly better than the estimated decline of 11.7% by five analysts [4] - The number of ending restaurants was 280, compared to the average estimate of 284 by five analysts [4] - Net new restaurant openings were 15, which is lower than the average estimate of 17 based on four analysts [4] Stock Performance - Sweetgreen's shares have returned -9% over the past month, while the Zacks S&P 500 composite has increased by 0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - DiamondRock Hospitality (DRH) reported revenue of $274.53 million for the quarter ended December 2025, reflecting a decrease of 1.6% year-over-year [1] - The company's EPS was $0.27, a significant improvement from -$0.07 in the same quarter last year, indicating a positive trend in earnings [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $274.95 million, resulting in a revenue surprise of -0.15% [1] - The company achieved an EPS surprise of +14.55%, surpassing the consensus estimate of $0.24 [1] Revenue Breakdown - Room revenues were reported at $178.16 million, which was lower than the estimated $179.62 million, marking a year-over-year decline of 2.7% [4] - Other revenues amounted to $27.66 million, exceeding the estimated $26.5 million, and showing a year-over-year increase of 4.4% [4] - Food and beverage revenues reached $68.71 million, slightly above the average estimate of $68.53 million, but represented a year-over-year decrease of 1% [4] Stock Performance - Over the past month, shares of DiamondRock Hospitality have returned +11.2%, outperforming the Zacks S&P 500 composite, which saw a change of +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Figs (FIGS) reported $201.9 million in revenue for the quarter ended December 2025, representing a year-over- year increase of 33%. EPS of $0.10 for the same period compares to $0.01 a year ago. Here is how Figs performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: View all Key Company Metrics for Figs here>>> Shares of Figs have returned -2.9% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has ...

For the quarter ended December 2025, Natera (NTRA) reported revenue of $665.5 million, up 39.8% over the same period last year. EPS came in at $0.35, compared to -$0.41 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $660.45 million, representing a surprise of +0.76%. The company delivered an EPS surprise of +175.43%, with the consensus EPS estimate being -$0.46. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...